Prothena_RGB_fullcolor.jpg
Prothena Reports First Quarter Financial Results
May 14, 2013 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, May 14, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena_RGB_fullcolor.jpg
First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis
April 23, 2013 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena_RGB_fullcolor.jpg
Prothena Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Research and Development Update
March 28, 2013 16:05 ET | Prothena Corporation plc
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc...
Prothena_RGB_fullcolor.jpg
Prothena Announces Appointments of Chief Medical Officer and Chief Financial Officer
March 25, 2013 16:30 ET | Prothena Corporation plc
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013
March 21, 2013 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
February 27, 2013 16:30 ET | Prothena Corporation plc
DUBLIN, Ireland, Feb. 27, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena to Ring NASDAQ Stock Market Opening Bell
February 13, 2013 06:00 ET | Prothena Corporation plc
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Announces Addition of Industry Veterans to Board of Directors
January 07, 2013 08:00 ET | Prothena Corporation plc
DUBLIN, Ireland, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
December 21, 2012 01:30 ET | Prothena Corporation plc
DUBLIN, Ireland, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...